Conference Vision

In the past few years, immune checkpoint inhibitors, such as PD-1, PD-L1, CTLA-4 mAb, CAR-T etc. have revolutionized treatment regimens for several cancers. Biologics have entered the center stage of drug discovery. As of February 2020, CGT products account for 12 percent of the industry’s clinical pipeline and at least 16 percent of the preclinical pipeline. As of Apr. 2021, over 100 antibody therapeutics have been approved.

Looking at China, China’s Made in China 2025 identified biopharma industry as one of ten key industries to target. Today, the development of new-generation innovative biologics, such as ADCs and CGTs, is well underway. China is one of the leading nations in the development of cell and gene therapies and is the second largest in the world for CAR-T clinical trials. China's pharmaceutical industry was undertaking a critical transformation toward high-quality and innovation-focused development.

Meanwhile, China's biopharma industry, with growing applications of digital technology to biologics innovation, AI, and bioprocessing technology such as continuous bioprocessing, will grow the number of made in China innovative biologics in the globe market.

With industry trends above, 5th Biologics Innovation and Frontier Technology (BIFT) China Summit 2022 will be held on October 20-21 in Shanghai. The event will gather 800 senior biologics professionals across the value chain to showcase their research, collaborate on challenges, forge new connections and ultimately advance the industry to improve patient health and maximize efforts and profit in the industry. The show will take a deep dive into the latest technologies, tools, analytical methods and best practices for the development of biologics and CGT in China.

From presentations exploring various biotherapeutic modalities (CGTs, mAbs, ADCs, bispecifics, nanobodies), engineering techniques and methods through to analytical method development, process development, formulation strategies for rapid biotherapeutics development and case studies, BIFT China 2022 is The Must-Attend Event for biopharma professionals to take away cutting edge technology and applications helping them to improve the quality, efficacy, cost, and compliance of their life-saving products. Join our event to learn and get inspired from leading industry experts and improve your business performance!


Produced by
Media Partners